Baykan M, Celik S, Uçar F, Kaplan S, Ovali E, Erdöl C
Karadeniz Teknik Universitesi Tip Fakültesi Kardiyoloji.
Anadolu Kardiyol Derg. 2001 Dec;1(4):242-5; AXIV.
Factor V Leiden mutation, the genetic defect underlying resistance to activated protein C, is the most common risk factor for venous thrombosis. Factor V Leiden mutation and its relation to post-myocardial infarction (MI) complications including angina pectoris, heart failure, reinfarction and cardiac mortality has not been investigated. We aimed to investigate this relation.
The prevalence of factor V Leiden mutation was investigated in 122 patients with first acute myocardial infarction (aged 56 +/- 11, 82 men/40 women). These patients were divided into two groups according to whether the patients had factor V Leiden mutation (Group I) or not (Group II). Post MI complications were evaluated during 18 months. Blood samples from the patients were analyzed for factor V Leiden mutation by DNA analysis, using the polymerase chain reaction (PCR).
Factor V Leiden was detected in 11 (9%) patients (aged; 54 +/- 10, 5 women/men) and was not detected in 111(90%) patients (aged; 56 +/- 11; 35 women/76 men) of the 122 patients. There were no significant differences between Group I and Group II in terms of post MI complications, including reinfarction (27% vs. 29%; p > 0.05, respectively), angina pectoris (45% vs. 38%; p > 0.05, respectively), heart failure (27% vs. 23%; p > 0.05, respectively) and cardiac mortality (18% vs. 14%; p > 0.05, respectively).
Post MI complications, including reinfarction, heart failure, angina pectoris and cardiac mortality were not increased in patients with factor V Leiden.
凝血因子V莱顿突变是导致对活化蛋白C产生抵抗的遗传缺陷,是静脉血栓形成最常见的危险因素。凝血因子V莱顿突变及其与心肌梗死后(MI)并发症(包括心绞痛、心力衰竭、再梗死和心脏死亡率)的关系尚未得到研究。我们旨在研究这种关系。
对122例首次发生急性心肌梗死的患者(年龄56±11岁,男性82例/女性40例)进行凝血因子V莱顿突变的患病率调查。根据患者是否存在凝血因子V莱顿突变,将这些患者分为两组(I组)和无凝血因子V莱顿突变组(II组)。在18个月期间评估心肌梗死后并发症。采用聚合酶链反应(PCR)通过DNA分析对患者的血样进行凝血因子V莱顿突变分析。
122例患者中,11例(9%)患者(年龄54±10岁,女性5例/男性6例)检测到凝血因子V莱顿突变,111例(90%)患者(年龄56±11岁,女性35例/男性76例)未检测到。I组和II组在心肌梗死后并发症方面无显著差异,包括再梗死(分别为27%对29%;p>0.05)、心绞痛(分别为45%对38%;p>0.05)、心力衰竭(分别为27%对23%;p>0.05)和心脏死亡率(分别为18%对14%;p>0.05)。
凝血因子V莱顿突变患者的心肌梗死后并发症,包括再梗死、心力衰竭、心绞痛和心脏死亡率并未增加。